| Cat. No. |
Product Name |
Information |
| PC-38910 |
Anselamimab
Anti-Serum Amyloid A mAb
|
Anselamimab (CAEL-101) is monoclonal antibody against serum amyloid A, directly targets human light-chain amyloid deposits and affects their removal via a phagocyte-mediated response, shows potential amyloidolytic effect. |
| PC-38881 |
Narsoplimab
Anti-MASP2 mAb
|
Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. |
| PC-38880 |
Ranevetmab
Anti-Canine NGF mAb
|
Ranevetmab is a caninized monoclonal antibody that targets nerve-growth factor (NGF), can be potentially used in the treatment of osteoarthritis (OA). |
| PC-38874 |
Zimberelimab
Anti-PD-1 mAb
|
GLS-010 (Zimberelimab, AB122) is a fully human, monoclonal immunoglobulin G4 (IgG4) anti-programmed death-1 (PD-1) antibody that shows promising efficacy and safety in advanced solid tumors. |
| PC-38873 |
Vudalimab
PD-1/CTLA-4 bispecific mAb
|
Vudalimab (XmAb 20717, XmAb 717) is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. |
| PC-38872 |
Vixarelimab
Anti-OSMRβ mAb
|
Vixarelimab (KPL-716) is a fully-human monoclonal antibody that targets oncostatin M receptor beta (OSMRβ), which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis. |
| PC-38871 |
Tusamitamab
Anti-CEACAM5 mAb
|
Tusamitamab is a monoclonal antibody anti-CEACAM5, component of monoclonal antibody-drug conjugate Tusamitamab ravtansine (SAR 408701). |
| PC-38870 |
Tarlatamab
DLL3/CD3 BiTE mAb
|
Tarlatamab (AMG 757) is a half-life extended bispecific T-cell engager (BiTE) molecule targeting delta-like ligand 3 (DLL3), a target that is selectively expressed in SCLC tumors, but with minimal normal tissue expression. |
| PC-38869 |
Recaticimab
Anti-PCSK9 mAb
|
Recaticimab (SHR-1209) is a humanized immunoglobulin G1 monoclonal antibody against PCSK9, showed robust LDL-C reduction in vivo. |
| PC-38868 |
Vopratelimab
Anti-ICOS (CD278) mAb
|
Vopratelimab (JTX-2011) is an agonist monoclonal antibody that binds to and activates ICOS, the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in many solid tumors. |
| PC-38867 |
Pimivalimab
Anti-PD-1 mAb
|
Pimivalimab (JTX-4014) is a fully human monoclonal antibody targeting PD-1, potentially resulting in restoration of anti-tumor immune response. |
| PC-38866 |
Penpulimab
Anti-PD-1 mAb
|
Penpulimab (AK 105) is a humanized anti-programmed cell death 1 (PD-1) monoclonal antibody. Isotype: IgG1-kappa. Anti-[human PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody. |
